Updated guidelines for chronic active Epstein-Barr virus disease.
CAEBV
Diagnostic criteria
EBV
Guidelines
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
28
04
2023
accepted:
06
09
2023
revised:
31
08
2023
medline:
2
11
2023
pubmed:
20
9
2023
entrez:
20
9
2023
Statut:
ppublish
Résumé
Chronic active Epstein-Barr virus disease (CAEBV), formerly named chronic active Epstein-Barr virus infection, is characterized by systemic inflammation and clonal proliferation of Epstein-Barr virus (EBV)-infected T or NK cells. As CAEBV is a potentially life-threatening illness, appropriate diagnosis and therapeutic interventions are necessary for favorable clinical outcomes. Substantial evidence regarding the pathogenesis and treatment of CAEBV has been accumulated since previous guidelines for the diagnosis of CAEBV were proposed. To reflect this evidence, we updated the guidelines for the diagnosis and treatment of CAEBV to improve clinical management of the disease. The details of the updated guidelines are presented in this report. Diagnosis of CAEBV now requires confirmation of a high copy number of EBV genome and EBV-infected T or NK cells. An EBV DNA load ≥ 10,000 IU/mL in whole blood is proposed as the diagnostic cutoff value for CAEBV in this updated guideline. A standard treatment approach for CAEBV has not been established, and hematopoietic stem cell transplantation (HSCT) is considered the only curative treatment. Chemotherapy can be administered to control disease activity before HSCT.
Identifiants
pubmed: 37728704
doi: 10.1007/s12185-023-03660-5
pii: 10.1007/s12185-023-03660-5
pmc: PMC10615970
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
568-576Subventions
Organisme : Ministry of Health, Labor, and Welfare of Japan
ID : 20FC1004
Organisme : Ministry of Health, Labour and Welfare
ID : 22FC1004
Informations de copyright
© 2023. The Author(s).
Références
J Dermatol. 2023 Jul;50(7):e198-e205
pubmed: 37249004
Blood. 2021 Jan 14;137(2):203-215
pubmed: 33443553
Ann Oncol. 2009 Sep;20(9):1472-1482
pubmed: 19515747
Blood. 2022 Sep 15;140(11):1229-1253
pubmed: 35653592
Clin Infect Dis. 2008 May 15;46(10):1525-34
pubmed: 18419486
Pathol Int. 1999 Jan;49(1):9-13
pubmed: 10227719
Blood. 2001 Jul 15;98(2):280-6
pubmed: 11435294
Blood. 2018 Jun 28;131(26):2899-2905
pubmed: 29712633
N Engl J Med. 1989 Feb 23;320(8):502-6
pubmed: 2536894
Pathology. 2020 Jan;52(1):111-127
pubmed: 31767131
Blood. 2016 Apr 21;127(16):2007-17
pubmed: 26744460
Am J Hematol. 2008 Sep;83(9):721-7
pubmed: 18626884
Nat Genet. 2015 Sep;47(9):1061-6
pubmed: 26192917
Blood Adv. 2022 Jan 25;6(2):452-459
pubmed: 34670275
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32812031
J Infect Dis. 2004 Sep 1;190(5):985-8
pubmed: 15295706
Oncotarget. 2016 Nov 22;7(47):76793-76805
pubmed: 27732937
Acta Paediatr Jpn. 1993 Oct;35(5):394-9
pubmed: 8256622
J Infect Chemother. 2016 Apr;22(4):268-71
pubmed: 26712582
Pathol Int. 2008 Apr;58(4):209-17
pubmed: 18324913
Nat Rev Microbiol. 2019 Nov;17(11):691-700
pubmed: 31477887
J Virol. 2011 Jan;85(1):165-77
pubmed: 20980506
Hematol Oncol. 2022 Aug;40(3):381-389
pubmed: 35405763
J Infect Dis. 2019 Sep 13;220(8):1307-1311
pubmed: 31240305
Adv Exp Med Biol. 2018;1045:459-475
pubmed: 29896680
J Infect Dis. 2005 Feb 15;191(4):531-9
pubmed: 15655776
Rev Med Virol. 2020 Mar;30(2):e2095
pubmed: 31845495
Blood. 2012 Jan 19;119(3):673-86
pubmed: 22096243
Int J Hematol. 2017 Apr;105(4):406-418
pubmed: 28210942
Biologicals. 2016 Sep;44(5):423-33
pubmed: 27461128
Blood. 2011 Jun 2;117(22):5835-49
pubmed: 21454450
Nat Microbiol. 2019 Mar;4(3):404-413
pubmed: 30664667
Bone Marrow Transplant. 2011 Jan;46(1):77-83
pubmed: 20498651
Clin Microbiol Rev. 1991 Jan;4(1):129-35
pubmed: 1848476
Blood Adv. 2020 Jul 14;4(13):2918-2926
pubmed: 32598475
Am J Hematol. 2005 Nov;80(3):207-12
pubmed: 16247742
J Infect Dis. 1988 Mar;157(3):405-12
pubmed: 2830340
Stem Cells Dev. 2022 Jan;31(1-2):26-31
pubmed: 34779276
Am J Hematol. 2022 Jun 1;97(6):780-790
pubmed: 35312194
Front Pediatr. 2019 Mar 15;7:71
pubmed: 30931288
Oncotarget. 2018 Jul 24;9(57):31077-31089
pubmed: 30123428
PLoS One. 2017 Mar 27;12(3):e0174136
pubmed: 28346502
J Infect Dis. 1989 Sep;160(3):546-7
pubmed: 2547884
Ann Intern Med. 1985 Jan;102(1):1-7
pubmed: 2578266
World J Pediatr. 2021 Dec;17(6):626-636
pubmed: 34739695
Am J Hematol. 2005 Sep;80(1):64-9
pubmed: 16138335
Lancet. 2000 Jul 15;356(9225):223-4
pubmed: 10963205
Biol Blood Marrow Transplant. 2014 Feb;20(2):214-21
pubmed: 24188918
Cancer Sci. 2012 Aug;103(8):1481-8
pubmed: 22497716
Proc Natl Acad Sci U S A. 1981 Feb;78(2):805-9
pubmed: 6262773
J Infect Dis. 2003 Feb 15;187(4):527-33
pubmed: 12599068
Front Immunol. 2017 Dec 22;8:1867
pubmed: 29375552
J Infect Dis. 2009 Oct 1;200(7):1078-87
pubmed: 19698076
Bone Marrow Transplant. 2000 Oct;26(7):805-8
pubmed: 11042666
Clin Cancer Res. 2014 Nov 1;20(21):5412-22
pubmed: 25208880